<DOC>
	<DOC>NCT02769533</DOC>
	<brief_summary>This study is focusing on patients presenting with suspected malignancies of the pituitary gland who are considered to be good surgical candidates.The primary end-point of the study is to determine the sensitivity of OTL38 uptake and expression in identifying those nodules when excited by an imaging probe.There will be a single dose of 0.025 mg/kg for intravenous injection over approximately 60 minutes, two to three hours, prior to surgery.</brief_summary>
	<brief_title>A Phase 1, Single Dose, Open-Label Study to Investigate the Safety and Efficacy of OTL38 Injection (OTL38) for Intra-operative Imaging of Folate Receptor-alpha Positive Pituitary Adenoma</brief_title>
	<detailed_description />
	<mesh_term>Adenoma</mesh_term>
	<mesh_term>Pituitary Diseases</mesh_term>
	<mesh_term>Pituitary Neoplasms</mesh_term>
	<mesh_term>Diphenhydramine</mesh_term>
	<criteria>Adult patients over 18 years of age Patients presenting with a pituitary nodule presumed to be resectable on preoperative assessment Good operative candidate Subject capable of giving informed consent and participating in the process of consent. Pregnant women as determined by urinary or serum beta hCG within 72 hours of surgery Patients with a history of anaphylactic reactions to OTL38 Patients with a known allergy to Benadryl Previous exposure to OTL38</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>